SGLT2 Inhibitors in Heart Failure: Evidence, Dosing, and Clinical Decision Points

The SGLT2 Inhibitor Revolution in Heart Failure

SGLT2 inhibitors have fundamentally changed heart failure management. Originally developed as glucose-lowering agents for type 2 diabetes, dapagliflozin and empagliflozin have demonstrated robust cardiovascular and mortality benefits across the entire spectrum of heart failure, regardless of diabetes status. This article reviews the key clinical trials and provides practical prescribing guidance for practicing clinicians.

DAPA-HF: Dapagliflozin in HFrEF

The DAPA-HF trial enrolled 4,744 patients with NYHA class II-IV heart failure and LVEF 40% or less. Dapagliflozin 10 mg daily reduced the primary composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI 0.65-0.85, p < 0.001). The benefit was consistent regardless of baseline diabetes status, with a 17% reduction in cardiovascular death (HR 0.82, 95% CI 0.69-0.98) and a 30% reduction in heart failure hospitalizations.

EMPEROR-Reduced: Empagliflozin Confirms the Class Effect

EMPEROR-Reduced enrolled 3,730 patients with HFrEF (LVEF 40% or less) and showed empagliflozin 10 mg daily reduced the primary composite endpoint by 25% (HR 0.75, 95% CI 0.65-0.86, p < 0.001). Importantly, the trial included patients with more severe heart failure (lower mean LVEF, higher NT-proBNP) than DAPA-HF, extending the evidence to sicker patients.